ELI LILLY WEIGHT LOSS PILL
Mounjaro sales dip amid price war as semaglutide generics gain ground
Mounjaro, the star pharmaceutical from Eli Lilly, is experiencing a downturn in sales across India. This slump can be attributed to competitor Novo Nordisk slashing prices on their famed Ozempic and Wegovy, not to mention the influx of cost-effective semaglutide generics. Despite this, Lilly remains optimistic about the distinct advantages Mounjaro brings to its users.
Novo Nordisk’s weight-loss drug patent loss sparks a ‘gold rush’ for generic drugmakers
India's weight-loss drug market is seeing a major shift. Generic versions of Novo Nordisk's semaglutide are now available at lower prices. This is impacting Eli Lilly's drug sales. The market is expected to grow significantly. Indian drugmakers are launching these affordable alternatives rapidly. This marks a new era for obesity treatments in the country.
Easy access to weight-loss drugs rings alarm bells among doctors, authorities; regulators step in
Weight-loss drugs are being sold without prescriptions in India. This is causing alarm among doctors and authorities. People are buying these medicines over the counter. They are ignoring medical advice on dosage and side effects. Social media and word-of-mouth are driving demand. This unregulated access poses a significant public health threat.
India's 'Mounjaro brides': Weight-loss injections become part of pre-wedding preparation
With wedding season in full swing, Indian health clinics are rolling out specialized weight-loss packages that include popular drugs such as Mounjaro and Wegovy. This emerging trend underscores the immense societal pressure to achieve a perfect look in a short span of time.
- Go To Page 1
Trump unveils 100% tariff on some patented drugs on 'Liberation Day' anniversary
President Donald Trump has signed an executive order introducing significant pharmaceutical tariffs. Companies failing to strike pricing deals with the administration face up to 100 per cent tariffs on patented drugs. Those building US facilities may see reduced or zero tariffs. This move aims to reshape drug pricing and boost domestic manufacturing.
Tariff therapy: Trump nudges pharma cos to make drugs in US or face 100% tariff
America is set to impose hefty 100% tariffs on imported medicines. This move targets drug companies that do not agree to government pricing deals or commit to manufacturing in the US. Companies have a limited time to comply. This aims to lower prescription drug costs for Americans. Exemptions and reduced rates are available for those meeting specific criteria.
Eli Lilly Foundayo weight loss pill price, side effects, dosage, treatment: When will sales for oral weight-loss drug begin?
Foundayo Eli Lilly weight loss pill: Eli Lilly drug, orforglipron, which will be sold under the brand name Foundayo, is a once-daily oral medication that targets the GLP-1 hormone.
Trump administration readies new tariffs on select drugmakers: Report
The Trump administration is reportedly preparing to impose 100% tariffs on drugmakers that haven't secured deals for lower U.S. prices. Several major pharmaceutical companies have already made pricing agreements or expanded U.S. operations to avoid these penalties. The plans are not finalized and may include exemptions for certain medicines.
Lilly's weight-loss pill wins US approval, sets up next battle with rival Novo Nordisk
The US FDA has approved Eli Lilly's new weight-loss pill, Foundayo. This marks a significant step in the ongoing competition with rival Novo Nordisk in the GLP-1 medicine market. Foundayo is an oral medication offering a new option for weight management. Lilly plans to launch the pill soon, with further global approvals expected this year.
US Stock Market | Wall Street ends higher on speculation about end to Iran war
Wall Street surged as President Trump hinted at a swift end to Middle East conflict, boosting tech giants like Alphabet. Investors are optimistic about de-escalation, despite ongoing inflation fears and mixed economic data. SpaceX's IPO filing and positive drug approvals also fueled market gains, though Nike saw a significant drop.
Dow Jones, S&P 500, Nasdaq gain as Trump signals possible end to Iran conflict: Intel, Eli Lilly, Alphabet, Meta, lead rally today and oil prices fall – here's how US stock market starts April
Dow Jones, S&P 500, Nasdaq today April 1: Stocks surged on Wednesday, led by major tech companies, as optimism grew regarding a potential end to the US conflict with Iran. Major indices like the S&P 500 and Nasdaq closed higher, influenced by President Trump's comments on de-escalation and a potential US military withdrawal. Oil prices fell as tensions eased, while airline stocks gained.
US Stocks Today | US stocks settle higher on speculation about end to Iran war
Wall Street climbed Wednesday, led by Alphabet, Meta, and Amazon, after President Trump suggested the Middle East conflict may be ending. The S&P 500 rose 0.72%, Nasdaq 1.17%, and Dow 0.49%. Oil prices dropped, Nike fell on weak sales guidance, and investors turned attention to inflation and upcoming U.S. payroll data.
Eli Lilly (LLY) stock soars after FDA approves Foundayo - can this weight-loss pill drive massive growth as investors bet big on obesity drug boom
Eli Lilly (LLY) stock today: Eli Lilly's stock surged over 5% following the US FDA's approval of its new oral weight-loss drug, Foundayo. This marks a significant expansion for Lilly in the lucrative obesity market. Clinical trials showed substantial weight loss, and the drug's accessible pricing strategy is expected to boost its adoption, strengthening Lilly's portfolio.
School assembly news headlines for April 2: Top national, international, business, sports update and thought of the day
Today's school assembly bulletin for April 2 covers significant national news, including bail granted in a Goa nightclub fire case and the Lok Sabha's decision to recognize Amaravati as Andhra Pradesh's sole capital. International headlines focus on President Trump's address regarding the Iran war and its impact on the beauty industry.
Novo Nordisk price cuts set to shake up India’s GLP-1 market, challenge generics
Novo Nordisk is slashing prices for its diabetes and weight loss drugs Ozempic and Wegovy in India. This move aims to make these treatments more accessible to patients. Industry experts believe this will significantly impact competition. Novo Nordisk's established reputation with doctors is also expected to help. The company hopes to gain a larger share of the GLP-1 market.
Novo Nordisk cuts Ozempic and Wegovy prices by up to 48% as GLP-1 competition intensifies in India
Novo Nordisk has significantly slashed prices for Ozempic and Wegovy in India, reducing them by 36% and 48% respectively, to enhance patient access. These new prices, effective April 1, aim to make the GLP-1 therapies more affordable for individuals managing diabetes and obesity. This move comes as Indian companies launch generic semaglutide following patent expiry, intensifying market competition.
Eli Lilly to buy Centessa in $6.3 billion deal for sleep medicines
Eli Lilly is acquiring Centessa Pharmaceuticals for approximately $6.3 billion, with an additional contingent value right potentially increasing the deal to $7.8 billion. This strategic move aims to bolster Lilly's offerings in the sleep-wake disorder treatment market. Centessa's shares saw a significant surge following the announcement.
24-year-old who lost 15 kgs without supplement in just 4 months, shares his ‘biggest’ weight loss mistake
A young individual detailed a significant fitness transformation, losing over 15 kilograms in four months by adopting a disciplined routine and improved nutrition. Despite past setbacks with inconsistent habits and insufficient protein, he has now achieved a maintenance phase and continues to navigate the challenge of preserving strength during fat loss.
Mounjaro maker signs $2.7 billion deal on AI drug research
The new deal builds on existing collaborations between the two companies, which struck a software licensing agreement in 2023, according to Insilico. The pair will use Insilico's "AI engine to accelerate the discovery and development of novel therapeutics across multiple therapeutic areas", said the filing, made by Insilico's parent company on Sunday.
Eli Lilly to sign $2 billion deal for AI drug development with Hong Kong's Insilico Medicine: Report
Lilly will acquire exclusive rights to sell a GLP-1 drug for diabetes from Insilico Medicine, the FT report said, citing sources familiar with the matter.
GLP-1 impact: Jefferies sees these 3 stocks as winners in the race for Ozempic, Wegovy generics
Indian drug makers are launching affordable generic Semaglutide, the active ingredient in popular weight-loss drugs. Sun Pharma, Lupin, and Torrent Pharma are identified as potential market leaders. Despite initial stockouts online, companies are adjusting supply. The market for these diabetes and obesity drugs is expected to grow significantly in India.
India is well positioned to attract future investments, says Eli Lilly's Patrik Jonsson
Eli Lilly's Patrik Jonsson urges India to accelerate regulatory review pathways to boost competitiveness, emphasizing the need for data protection and harmonized guidelines. He highlighted India's potential for investment, driven by its scientific talent, while addressing affordability concerns by noting localized pricing strategies.
India is well positioned to attract future investments: Patrik Jonsson, President, Lilly International
Eli Lilly's Patrik Jonsson urges India to accelerate regulatory review pathways to boost competitiveness, emphasizing the need for stronger data protection and alignment with international guidelines. He highlighted that while India is well-positioned for investment, these improvements are crucial for attracting high-value research and ensuring timely access to innovative therapies.
A blockbuster unleashed: What happens when a big fat business explodes?
India is set to experience a dramatic shift as Ozempic and Wegovy's active ingredient, semaglutide, becomes widely available. Over 40 Indian companies are launching affordable generic versions, slashing prices and expanding access. This transition promises to address major health challenges but also raises concerns about potential misuse and the need for strong oversight.
Natco, Eris Life to launch slimming shots in both Vial and Pen formats
Natco Pharma and Eris Lifesciences are launching generic semaglutide weight-loss injections. The companies are introducing both vial and pen formats. This move aims to make the treatment more affordable. Vials will be available first, targeting a wider patient base. Pens are expected later for metropolitan markets. This strategy offers patients pricing flexibility.
Novo to track generic surge as semaglutide goes off patent
Novo Nordisk is preparing for a surge of generic semaglutide drugs in India. The company's India head stated they will monitor rivals' pricing and market strategies closely. With many companies launching cheaper versions, Novo Nordisk plans to evaluate the market before reacting. This move comes as the blockbuster diabetes and weight-loss drug's patent expires.
Load More
